Rosen's Breast Pathology, 4e

410

Chapter 11

399. Silverstein MJ. Incidence and treatment of ductal carcinoma in situ of the breast. Eur J Cancer 1997;33:10–11. 400. de Mascarel I, Bonichon F, MacGrogan G, et al. Application of the Van Nuys prognostic index in a retrospective series of 367 ductal carcinomas in situ of the breast examined by serial macro- scopic sectioning: practical considerations. Breast Cancer Res Treat 2000;61:151–159. 401. Boland GP, Chan KC, Knox WF, et al. Value of the Van Nuys Prog- nostic Index in prediction of recurrence of ductal carcinoma in situ after breast-conserving surgery. Br J Surg 2003;90:426–432. 402. Warnberg F, Nordgren H, Bergh J, et al. Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new his- topathological classification systems. Eur J Cancer 1999;35:714–720. 403. Silverstein MJ. Ductal carcinoma in situ of the breast: the Van Nuys experience by treatment. Breast J 1997;3:232–237. 404. Solin LJ, McCormick B, Recht A, et al. Mammographically detected, clinically occult ductal carcinoma in situ treated with breast-con- serving surgery and definitive breast irradiation. Cancer J Sci Am 1996;2:158–165. 405. Fowble B. The results of conservative surgery and radiation for mammographically detected ductal carcinoma in situ . Breast J 1997;3:238–241. 406. Silverstein MJ, Lagios MD, Martino S, et al. Outcome after invasive local recurrence in patients with ductal carcinoma in situ of the breast. J Clin Oncol 1998;16:1367–1373. 407. Silverstein MJ, Lagios MD. Choosing treatment for patients with ductal carcinoma in situ : fine tuning the University of Southern California/Van NuysPrognostic Index. J Natl Cancer Inst Monogr 2010;2010(41):193–196. 408. Altintas S, Toussaint J, Durbecq V, et al. Fine tuning of the Van Nuys prognostic index (VNPI) 2003 by integrating the genomic grade in- dex (GGI): new tools for ductal carcinoma in situ (DCIS). Breast J 2011;17:343–351. 409. Kelley L, Silverstein M, Guerra L. Analyzing the risk of recurrence af- ter mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index. Ann Surg Oncol 2011;18:459–462. 410. Rudloff U, Jacks LM, Goldberg JI, et al. Nomogram for predicting the risk of local recurrence after breast-conserving surgery for ductal car- cinoma in situ . J Clin Oncol 2010;28:3762–3769. 411. Yim, Meric-Bernstein F, Kuerer HM, et al. Evaluation of a breast can- cer nomogram for predicting risk of ipsilateral breast tumor recur- rence in patients with ductal carcinoma in situ after local excision. J Clin Oncol 2012;30:600–607. 412. Thomas M, Goldstein NS, Vicini FA, et al. The association of age at diagnosis with pathologic features in patients with duct carcinoma in situ of the breast. Mod Pathol 2000;13:47A. 413. Adepoju LJ, Symmans WF, Babiera GV, et al. Impact of concurrent proliferative high-risk lesions on the risk of ipsilateral breast carci- noma recurrence and contralateral breast carcinoma development in patients with ductal carcinoma in situ treated with breast-conserving therapy. Cancer 2006;106:42–50. 414. Cuzick J, Sestak I, Pinder SE, et al. Effect of tamoxifen and radiother- apy in women with locally excised ductal carcinoma in situ : long-term results from the UK/ANZ DCIS trial. Lancet Oncol 2011;12:21–29. 415. Fisher B, Dignam J, Wolmark N, et al. Tamoxifen in treatment of in- traductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet 1999;353:1993–2000. 416. Allred DC, Anderson SJ, Paik S, et al. Adjuvant tamoxifen reduces subsequent breast cancer in women with estrogen receptor-positive ductal carcinoma in situ : a study based on NSABP protocol B-24. J Clin Oncol 2012;30:1268–1273. 417. Vogel VG, Costantino JP, Wickerham DL, et al. Update of the Na- tional Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res (Phila) 2010;3:696–706. 418. Morrow M, O’Sullivan MJ. The dilemma of DCIS. Breast 2007;16(Suppl. 2):S59–S62. 419. Allegra CJ, Aberle DR, Ganschow P, et al. National Institutes of Health State-of-the-Science Conference statement: diagnosis and manage- ment of ductal carcinoma in situ, September 22–24, 2009. J Natl Can- cer Inst 2010;102:161–169. 420. Cutuli B, Lemanski C, Fourquet A, et al. Breast-conserving surgery with or without radiotherapy vs mastectomy for ductal carcinoma in situ : French Survey experience. Br J Cancer 2009;100:1048–1054.

377. MacDonald HR, Silverstein MJ, Mabry H, et al. Local control in duc- tal carcinoma in situ treated by excision alone: incremental benefit of larger margins. Am J Surg 2005;190:521–525. 378. Wong JS, Kaelin CM, Troyan SL, et al. Prospective study of wide ex- cision alone for ductal carcinoma in situ of the breast. J Clin Oncol 2006;24:1031–1036. 379. Montague ED. Conservative surgery and radiation therapy in the treatment of operable breast cancer. Cancer 1984;53:700–704. 380. Solin LJ, Gray R, Baehner FL. A quantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without ir- radiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS score from ECOG E5194. Presented at: the 2011 CTRC-AACR San Antonio Breast Cancer Symposium; December 6–10, 2011 (Abstract S4–S6). 381. Prat A, Perou CM. Deconstructing the molecular portraits of breast cancer. Mol Oncol 2011;5:5–23. 382. Recht A, Danoff BS, Solin LJ, et al. Intraductal carcinoma of the breast: results of treatment with excisional biopsy and irradiation. J Clin On- col 1985;3:1339–1343. 383. Zafrani B, Fourquet A, Vilcoq JR, et al. Conservative management of intraductal breast carcinoma with tumorectomy and radiation ther- apy. Cancer 1986;57:1299–1301. 384. Bornstein BA, Recht A, Connolly JL, et al. Results of treating ductal carcinoma in situ of the breast with conservative surgery and radiation therapy. Cancer 1991;67:7–13. 385. Solin LJ, Recht A, Fourquet A, et al. Ten-year results of breast- conserving surgery and definitive irradiation for intraductal carcinoma (ductal carcinoma in situ ) of the breast. Cancer 1991;68:2337–2344. 386. Solin LJ, Fourquet A, Vicini FA, et al. Long-term outcome after breast- conservation treatment with radiation for mammographically detected ductal carcinoma in situ of the breast. Cancer 2005;103:1137–1146. 387. Fisher B, Land S, Mamounas E, et al. Prevention of invasive breast cancer in women with ductal carcinoma in situ : an update of the na- tional surgical adjuvant breast and bowel project experience. Semin Oncol 2001;28:400–418. 388. Julien JP, Bijker N, Fentiman IS, et al. Radiotherapy in breast- conserving treatment for ductal carcinoma in situ : first results of the EORTC randomised phase III trial 10853. EORTC Breast Can- cer Cooperative Group and EORTC Radiotherapy Group. Lancet 2000;355:528–533. 389. Bijker N, Meijnen P, Peterse JL, et al. Breast-conserving treatment with or without radiotherapy in ductal carcinoma-in-situ: ten-year results of European Organisation for Research and Treatment of Can- cer randomized phase III trial 10853—a study by the EORTC Breast Cancer Cooperative Group and EORTC Radiotherapy Group. J Clin Oncol 2006;24:3381–3387. 390. Kane RL, Virnig BA, Shamliyan T, et al. The impact of surgery, ra- diation, and systemic treatment on outcomes in patients with ductal carcinoma in situ . J Natl Cancer Inst Monogr 2010;2010(41):130–133. 391. Punglia RS, Burstein HJ, Weeks JC. Radiation therapy for ductal carci- noma in situ : a decision analysis. Cancer 2012;118:603–611. 392. Zauls AJ, Watkins JM, Wahlquist AE, et al. Outcomes in women treated with MammoSite brachytherapy or whole breast irradiation stratified by ASTRO Accelerated Partial Breast Irradiation Consensus Statement Groups. Int J Radiat Oncol Biol Phys 2012;82:21–29. 393. Park SS, Grills IS, Chen PY, et al. Accelerated partial breast irradia- tion for pure ductal carcinoma in situ . Int J Radiat Oncol Biol Phys 2011;81:403–408. 394. Wong P, Lambert C, Agnihotram RV, et al. Ductal carcinoma in situ — the influence of the radiotherapy boost on local control. Int J Radiat Oncol Biol Phys 2012;82:e153–e158. 395. Arvold ND, Punglia RS, Hughes ME, et al. Pathologic characteristics of second breast cancers after breast conservation for ductal carci- noma in situ . Cancer 2012;118:6022–6030. 396. Solin LJ, Yeh I-T, Kurtz J, et al. Ductal carcinoma in situ (intraductal carcinoma) of the breast treated with breast-conserving surgery and definitive irradiation. Correlation of pathologic parameters with out- come of treatment. Cancer 1993;71:2532–2542. 397. Kuske RR, Bean JM, Garcia DM, et al. Breast conservation therapy for intraductal carcinoma of the breast. Int J Radiat Oncol Biol Phys 1993;26:391–396. 398. Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999;86:429–438.